On November 19, 2025 Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I (Idea to IND), reported a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Pfizer will gain global rights to access Nona’s proprietary HCAb platform to generate fully human heavy chain-only antibodies. Nona Biosciences will receive an upfront payment and be eligible for regulatory, clinical, and commercial milestone payments. In addition, Nona may collaborate with Pfizer for antibody discovery, development, and engineering, leveraging Nona’s HCAb platform, advanced B-cell screening technologies, and integrated services.

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, commented: "We are pleased to continue providing support for Pfizer’s preclinical antibody discovery. By leveraging our fully human HCAbs, we aim to accelerate the discovery and development of transformative therapies for patients worldwide."

(Press release, Nona Biosciences, NOV 19, 2025, View Source [SID1234660087])